Table II.
Results from the in vitro study.
| DAB concentration | APCr ratio | p | p | p | p | p | |
|---|---|---|---|---|---|---|---|
| D | 0 ng/mL | 3.45±0.44 | |||||
| E | 6 ng/mL | 4.42±0.47 | D vs E p<0.01 | ||||
| F | 12 ng/mL | 4.82±1.05 | D vs F p<0.005 | E vs F p<0.05 | |||
| G | 25 ng/mL | 5.05±0.77 | D vs G p<0.001 | E vs G p<0.01 | F vs G p<0.05 | ||
| H | 50 ng/mL | 5.16±0.66 | D vs H p<0.001 | G vs H p<0.01 | F vs H p<0.01 | G vs H p<0.05 | |
| I | 100 ng/mL | 6.44±1.15 | D vs I p<0.001 | E vs I p<0.001 | F vs I p<0.01 | G vs I p<0.01 | H vs I p<0.01 |
| DAB concentration | APCr ratio | ||||||
| D1 | 0 ng/mL | 1.33±0.12 | |||||
| E1 | 6 ng/mL | 1.66±0.15 | D1 vs E1 p<0.05 | ||||
| F1 | 12 ng/mL | 1.79±0.14 | D1 vs F1 p<0.01 | E1 vs F1 p<0.05 | |||
| G1 | 25 ng/mL | 1.97±0.18 | D1 vs G1 p<0.005 | E1 vs G1 p<0.01 | F1 vs G1 p<0.05 | ||
| H1 | 50 ng/mL | 2.41±0.40 | D1 vs H1 p<0.001 | E1 vs H1 p<0.01 | F1 vs H1 p<0.01 | G1 vs H1 p<0.05 | |
| I1 | 100 ng/mL | 2.59±0.48 | D1 vs I1 p<0.001 | E1 vs I1 p<0.01 | F1 vs I1 p<0.01 | G1 vs I1 p<0.01 | H1 vs I1 p<0.05 |
APCr: activated protein C resistance; DAB: dabigatran etexilate. Plasma samples from normal subjects (FV wild-type homozygotes): groups D, E, F, G, H and I. Plasma samples from heterozygous FVL carriers: groups D1, E1, F1, G1, H1 and I1.